Clinical Significance of Acute Neurohormonal Response After Levosimendan Treatment

American Journal of Cardiology

Volumn 98, Issue 8, 2006, Pages 1123-1124

  Giannakoulas, George ^a   Giannoglou, George ^a   Vassilikos, Vasilis ^a   Martiadou, Kostantina ^a   Kalpidis, Panagiotis ^a   Parharidis, George ^a   Louridas, George ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LEVOSIMENDAN;

DRUG RESPONSE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS;

AGED; CARDIOTONIC AGENTS; FOLLOW-UP STUDIES; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MALE; NATRIURETIC PEPTIDE, BRAIN; PYRIDAZINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33749236392     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.007     Document Type: Letter

References (9)

1. Adamopoulos S., Parissis J.T., Iliodromitis E.K., Paraskevaidis I., Tsiapras D., Farmakis D., Karatzas D., Gheorghiade M., Filippatos G.S., and Kremastinos D.T. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98 (2006) 102-106
2. Mueller T., Gegenhuber A., and Haltmayer M. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int J Cardiol 104 (2005) 355-356
3. Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., Venetsanou K., Lekakis J., and Kremastinos D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 (2005) 423-426
4. Avgeropoulou C., Andreadou I., Markantonis-Kyroudis S., Demopoulou M., Missovoulos P., Androulakis A., and Kallikazaros I. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7 (2005) 882-887
5. Kyrzopoulos S., Adamopoulos S., Parissis J.T., Rassias J., Kostakis G., Iliodromitis E., Degiannis D., and Kremastinos D.T. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 (2005) 409-413
6. 1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail 7 (2005) 1156-1163
7. McLean A.S., Huang S.J., Nalos M., and Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 46 (2005) 830-835
8. Gegenhuber A., Mueller T., Firlinger F., Lenz K., Poelz W., and Haltmayer M. Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clin Chem 50 (2004) 454-456
9. Maeda K., Tsutamoto T., Wada A., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., and Kinoshita M. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587-1593